logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Dupilumab in addition to controller medications for children aged 6 to 11 years with asthma

< Back

Dupilumab in addition to controller medications for children aged 6 to 11 years with asthma

Drugs

Cardiovascular Disease and Vascular Surgery

May 2021


Dupilumab is in clinical development as an add-on to controller medications for the maintenance treatment in children aged 6 to <12 years with uncontrolled, moderateto-severe asthma. Asthma is a common lung condition that causes wheezing, coughing and breathlessness. Individuals with asthma can suffer an asthma attack, which in severe cases can be fatal. Patients with severe asthma have ongoing daily symptoms despite high-intensity asthma treatment. Therefore, there is need for additional treatment strategies which includes a need for biological therapies. Dupilumab is a targeted biological therapy that is taken subcutaneously. It acts by blocking certain proteins called interleukin-4 (IL-4) and interleukin-13 (IL-13) and mediates the pathways involved in the inflammatory process in asthma. If licensed, dupilumab will offer an additional add-on maintenance treatment option for children aged ≥ 6 to < 12 years with moderate-to-severe asthma that is uncontrolled on current treatment.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts